Although, these results are somewhat preliminary and need further confirmation with in vivo studies, they suggest a promising role for DDAH1 inhibition as a novel treatment strategy in triple negative breast cancer. This evidence concerns the gene DDAH1 and triple-negative breast carcinoma.